Related Experiment Video
Updated: Jan 19, 2026
Generating a Multivalent-Displaying Outer Membrane Vesicle Vaccine
Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy
Yingxuan Zhang1, Zheyan Fang1, Ruizhen Li1
1Department of Medical Microbiology, School of Medicine, Nanchang University, Nanchang 330006, China.
Abstract:
Cancer vaccines have been extensively studied in recent years and have contributed to exceptional achievements in cancer treatment. They are some of the most newly developed vaccines, although only two are currently approved for use, Provenge and Talimogene laherparepvec (T-VEC). Despite the approval of these two vaccines, most vaccines have been terminated at the clinical trial stage, which indicates that although they are effective in theory, concerns still exist, including low antigenicity of targeting antigens and tumor heterogeneity. In recent years, with new understanding of the biological function and vaccine potential of outer membrane vesicles (OMVs), their potential application in cancer vaccine design deserves our attention. Therefore, this review focuses on the mechanisms, advantages, and prospects of OMVs as antigen-carrier vaccines in cancer vaccine development. We believe that OMV-based vaccines present a safe and effective cancer therapeutic option with broad application prospects.
Insights
Outer membrane vesicles (OMVs) show promise as a novel platform for cancer vaccines. This review explores their potential to overcome challenges in current cancer vaccine development, offering a safe and effective therapeutic option.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer vaccines represent a significant advancement in oncology, yet challenges like low antigenicity and tumor heterogeneity limit their efficacy.
- Currently, only two cancer vaccines, Provenge and Talimogene laherparepvec (T-VEC), are approved, with many others failing in clinical trials.
Purpose of the Study:
- This review examines the potential of outer membrane vesicles (OMVs) as a novel antigen-carrier system for cancer vaccine development.
- It focuses on the mechanisms, advantages, and future prospects of utilizing OMVs in cancer immunotherapy.
Main Methods:
- Review of existing literature on cancer vaccines and outer membrane vesicles (OMVs).
- Analysis of OMV properties relevant to antigen presentation and immune stimulation.
- Evaluation of OMV-based vaccine strategies in preclinical and clinical contexts.
Main Results:
- Outer membrane vesicles (OMVs) possess biological functions and vaccine potential that make them attractive for cancer vaccine design.
- OMVs can serve as effective carriers for tumor antigens, potentially enhancing immune responses.
- Their application may help address limitations of traditional cancer vaccines, such as low antigenicity and tumor heterogeneity.
Conclusions:
- OMV-based cancer vaccines offer a promising, safe, and effective therapeutic strategy.
- Further research into OMV applications could lead to significant advancements in cancer treatment and immunotherapy.
Related Concept Videos
05:41Generating a Multivalent-Displaying Outer Membrane Vesicle Vaccine
10:21Directed Protein Packaging within Outer Membrane Vesicles from Escherichia coli: Design, Production and Purification
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
08:45Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
12:43Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells